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There was an error in the second sentence of the legend for Figure
2. The correct sentence is as follows:
The pathway of the tip of the re-entrant wave front circled in a
counterclockwise direction (A to E) around the insertion site
of a large pectinate muscle to the underlying atrial tissue (see
Fig. 1B).
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Kawai Y, Tsukamoto E, Nozaki Y, Morita K, Sakurai M,
Tamaki N. Significance of Reduced Uptake of Iodinated Fatty
Acid Analogue for the Evaluation of Patients With Acute
Chest Pain. J Am Coll Cardiol 2002;38:1888 –94.
The affiliation for Dr. Nagara Tamaki was incorrectly listed. Dr.
Tamaki belongs to the Department of Nuclear Medicine, Hok-
kaido University, School of Medicine, Sapporo, Japan. The correct
affiliation is: Nagara Tamaki, MD†.
The second sentence of the Results section of the Abstract was
incorrect. The correct sentence is: Of 24 patients without coronary
stenosis or spasm, 22 showed normal BMIPP SPECT (speci-
ficity  92%) and 23 showed normal tetrofosmin SPECT
(specificity  96%).
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Opie LH, Schall R. Evidence-Based Evaluation of Calcium
Channel Blockers for Hypertension: Equality of Mortality and
Cardiovascular Risk Relative to Conventional Therapy. J Am
Coll Cardiol 2002;39:315–22.
The authors have noted an error in Table 2 and Figure 1. The
major implication is that reduction of nonfatal stroke associated
with CCB use for hypertension does not outweigh but almost
exactly balances the increase in MI. Corrected data show a relative
risk for nonfatal stroke of 0.842 (p  0.013). The relative risk for
nonfatal MI remains 1.17 (p  0.036). Respective Bonferroni-
corrected p values for nonfatal stroke and nonfatal MI are 0.052
and 0.144. In addition, in type 2 diabetics, CCBs increased major
cardiovascular events with relative risk not of 1.258 but of 1.339
(confidence intervals 1.074 to 1.670, p  0.010), thereby more
strongly supporting the provisional hypothesis that CCBs may
be less safe than ACE inhibitors in diabetics. The revised Table
2 and Figure 1 are printed here. The authors apologize for the
error.
Table 6. Final Multiple Logistic Regression Model Predicting Six-Month Mortality in Patients
Who Survived  10 Days After CABG
Characteristics Odds Ratio 95% CI p Value
Ejection fraction (35% vs. 35%) 2.93 1.65–5.22 0.001
Congestive heart failure 2.14 1.23–3.74 0.01
Peripheral vascular disease 2.25 1.35–3.75 0.01
Cardiac arrhythmias 2.39 1.45–3.95 0.001
Retrograde cardioplegia 0.33 0.19–0.59 0.001
Number of arterial bypass grafts 0.65 0.46–0.92 0.05
Peak CK-MB enzyme ratio
 5 ULN 1.00
 5 and  10 ULN 1.98 1.08–3.62 0.05
 10 and  20 ULN 2.11 1.01–4.42 0.05
 20 ULN 4.95 2.47–9.95 0.001
Abbreviations as in Tables 1 and 2.
PII S0735-1097(02)01845-4
1409JACC Vol. 39, No. 8, 2002 Corrections
April 17, 2002:1407–10
